Stock analysts at StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the basic materials company’s stock.
A number of other equities analysts have also issued reports on RKDA. Lake Street Capital raised Arcadia Biosciences to a “strong-buy” rating in a research report on Tuesday, May 14th. HC Wainwright cut their price target on shares of Arcadia Biosciences from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd.
Read Our Latest Report on RKDA
Arcadia Biosciences Stock Down 1.6 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.74. The firm had revenue of $1.26 million during the quarter, compared to analysts’ expectations of $1.20 million. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. During the same period in the prior year, the company earned ($3.83) EPS. As a group, equities research analysts anticipate that Arcadia Biosciences will post -2.29 earnings per share for the current year.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How Can Investors Benefit From After-Hours Trading
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.